NASDAQ:GLPG

Galapagos Stock Forecast, Price & News

$60.54
0.00 (0.00 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$60.44
$61.24
50-Day Range
$57.23
$80.67
52-Week Range
$56.79
$195.74
Volume148,800 shs
Average Volume303,574 shs
Market Capitalization$3.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.55
30 days | 90 days | 365 days | Advanced Chart
Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.


Galapagos logo

About Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

1010th out of 2,220 stocks

Pharmaceutical Preparations Industry

480th out of 869 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 2 sell ratings, 10 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos
or view top-rated stocks.

What stocks does MarketBeat like better than Galapagos?

Wall Street analysts have given Galapagos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galapagos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galapagos?

Galapagos saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 582,100 shares, a drop of 30.0% from the June 15th total of 831,000 shares. Based on an average daily volume of 247,300 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.9% of the shares of the stock are sold short.
View Galapagos' Short Interest
.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Galapagos
.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) announced its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.71) by $1.47. The biotechnology company had revenue of $137.29 million for the quarter, compared to analyst estimates of $104.06 million. Galapagos had a negative trailing twelve-month return on equity of 10.05% and a negative net margin of 45.08%.
View Galapagos' earnings history
.

How has Galapagos' stock price been impacted by Coronavirus?

Galapagos' stock was trading at $186.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLPG stock has decreased by 67.5% and is now trading at $60.54.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GLPG?

17 analysts have issued 1 year target prices for Galapagos' stock. Their forecasts range from $65.80 to $170.00. On average, they expect Galapagos' stock price to reach $125.78 in the next year. This suggests a possible upside of 107.8% from the stock's current price.
View analysts' price targets for Galapagos
or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?

Galapagos' management team includes the following people:
  • Onno van de Stolpe, Chief Executive Officer
  • Bart Filius, President & Chief Operating Officer
  • Piet Wigerinck, Chief Scientific Officer
  • Walid Abi-Saab, Chief Medical Officer
  • Andre Hoekema, Chief Business Officer

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Galapagos' key competitors?

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), The Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%), Henry James International Management Inc. (0.05%), Moody National Bank Trust Division (0.01%) and Atlas Capital Advisors LLC (0.00%).

Which major investors are selling Galapagos stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Moody National Bank Trust Division, and Henry James International Management Inc..

Which major investors are buying Galapagos stock?

GLPG stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP, and Atlas Capital Advisors LLC.

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $60.54.

How much money does Galapagos make?

Galapagos has a market capitalization of $3.97 billion and generates $605.66 million in revenue each year. The biotechnology company earns $-348,900,000.00 in net income (profit) each year or ($5.36) on an earnings per share basis.

How many employees does Galapagos have?

Galapagos employs 1,304 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

Where are Galapagos' headquarters?

Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.